Life Sciences Archive » March, 2025

Life Sciences - March, 2025

281 articles

• Texas Judge Deems Lab-Test Rule Outside FDA Authority
• Former Stimlabs Exec Must Face Trade Secrets Claims
• Ex-Blood Bank Atty Goes Back To Ballard Spahr In Phoenix
• Nasdaq's Tighter IPO Rules Raise Bar For Small Companies
• Buyer Class Of Surgical Robots Is Certified In Antitrust Fight
• J&J Talc Spinoff's Ch. 11 Case Gets Tossed, Erasing $9B Deal
• Despite 'Admirable' Effort, Vertex Kickback Challenge Fails
• Pierson Ferdinand Adds Taylor English Health Pro In Atlanta
• Firms Must Embrace Alternative Billing Models Or Fall Behind
• Key Issues To Watch As USPTO Changes Abound
• Cleary Gains 5-Atty Latham Team Known For Big IP Wins
• Colo. Beats Amgen's Drug Price Cap Challenge, For Now
• Janssen Owes Additional $1.5B In HIV Prescription Trial
• PE Firm Hits Back Against Medical Device Coating Challenge
• Purdue Lawsuit Injunction Extended Ahead Of Plan Hearings
• Pot Co.'s Challenge To DEA Admin Procedures Dismissed
• 13 Drugmakers Seek Dismissal Of Aetna's Price-Fixing Claims
• Labcorp Denied Early Win In 401(k) Fee Suit
• Azzur Judge OKs At Least $1.3M In Potential Exec Bonuses
• Trending At The PTAB: A Pivot On Discretionary Denials
• 3rd Circ. Preview: April Arguments Feature Class Action Rows
• Fed. Circ. Upholds Janssen's Patent Case Win Over Mylan
• CureVac RNA Vax Patent Survives BioNTech's EU Challenge
• How Attorneys Can Master The Art Of On-Camera Presence
• Taxation With Representation: Norton Rose, Latham, Ashurst
• Jury Clears Lab Owners In $40M COVID Test Fraud Case
• Diopsys Inks $14M Deal Resolving Vision Testing FCA Claims
• New Procedures Expected To Result In More PTAB Denials
• Vaping Interests Take Challenge To FDA Rule To 5th Circ.
• Fertility Co. Wants To Pull Device Maker Into Negligence Suit 
• Texas Judge 'Disturbed' By Filings In Weight Loss Drug Case
• Fed. Circ. Revives Recor's PTAB Challenge To Medtronic IP
• Fitch Even Sues Ex-IP Client In Effort To End Malpractice Case
• Oura Gets Samsung's Preemptive IP Strike Tossed, For Now
• Ga. Therapy Clinic Accused Of Refusing OT Payments
• Patent Drafting Pointers From Fed. Circ. COVID Test Ruling
• Congress Must Reform The PTAB To Protect Small Innovators
• Eli Lilly Says Michigan AG's Insulin Pricing Probe Is Baseless
• Walgreens To Pay $2.8M For Alleged Medicaid Overcharges
• Mich. Judge Deflects Criticism Of Atty Fees In $53M Flint Deal
• Fox Rothschild Brings On McCarter & English IP Ace In NJ
• Baseball Fantasy Camp Makes Me A Better Lawyer
• Texas Law Firm Must Face 2nd Firm's Paxil Fees Suit
• Top EU Court Urged To Uphold €60M Teva Pay-For-Delay Fine
• 1st Circ. Denies Gov't Bid To Enforce Funding Freeze
• HHS To Cut 10,000 Jobs As RFK Jr. Reorganizes Agency
• Sotomayor Urges Caution On Nondelegation Doctrine Revamp
• 7 Firms Compete To Lead Novo Nordisk Securities Suit
• 23andMe Says Ch. 11 Privacy Ombudsman Not Required
• Full Fed. Circ. Won't Look At Injunction On MSN's Generic Drug
• Drugmaker Execs Hid Approval Process Roadblocks, Suit Says
• Women Make Up 13% Of Attys In Front Of The PTAB
• Walgreens, Kroger Claim Takeda Cut Illegal TWi Generics Deal
• Del. Justices Back Axing Suit Over $3B AstraZeneca Viela Sale
• AGs Seek 1st OK For $39M Apotex Deal In Price-Fixing Case
• False COVID Cure Claims No Longer Feds' 'Current Priority'
• Adapting To Private Practice: From Fed. Prosecutor To BigLaw
• Fla. Appeals Court Upholds Fees For Medical Pot Businesses
• Need For Individual Analyses Sinks Class Bid In Vax Bias Suit
• Ex-Masimo CEO Slams Bid To DQ His Hueston Hennigan Attys
• Medical Image Co. Gets Fed. Circ. To Back Ax Of Rival's IP
• Drug Co. Wants Fed. Circ. To Undo Pfizer COVID Patent Win
• What To Expect For Stem Cell Regulation Under Trump Admin
• Pension Seeks To Opt Class Out Of Cutera Ch. 11 Releases
• McCarter & English's $3.77M Fee Win Headed For Appeal
• Merck Betting Up To $2B On China-Developed Cardio Drug
• Meitar-Led Navina Wraps $55M Series C Funding Round
• 4th Circ. Won't Rehear Drug Price-Fixing Class Action
• Trump Picks Acting CDC Head After Weldon Nomination Fails
• Amgen Wants $50M Leukemia Drug Patent Verdict Thrown Out
• Kenvue, J&J Must Face Investor Suit Over FDA Concerns
• Justices Urged To Weigh In On Skinny Label Dispute
• Period App Users Get $3.5M In Privacy Deal With Analytics Co.
• United Healthcare Escapes Some Of Diagnostic Co.'s Claims
• Investors Blame Electrotherapy Co.'s Practices For Stock Drop
• Seattle Biotech Duped Investors On Drug Progress, Suit Says
• Apple, Sony, Others Facing ITC Probes Over Imports
• Fla. Judge OKs $19.3M In Spinal Products Noncompete Suit
• Norton Rose, Latham Steer Alcon's $430M Lensar Buy
• Firms Still Have Lateral Market Advantage, But Risks Persist
• Novartis Urges Court To Make FDA Block Entresto Generic
• Fed. Circ. Revives Blood Pump Patent Suit Against J&J Unit
• 10 Practical Takeaways From FDA's Biopharma AI Guidance
• Bausch & Lomb Says Amcor Must Pay For Botched Bottles
• Judge Accused Of Bias Expresses Regret Over MDL Remarks
• We Must Allow Judges To Use Their Independent Judgment
• New Mexico Lawmakers Approve Medical Psilocybin Bill
• Exactech Strikes $10M Deal With TPG In Ch. 11
• Taxation With Representation: Cravath, Paul Weiss, Cooley
• AstraZeneca To Invest $2.5B In China Research Hub
• Fed. Circ. Backs Actavis' $12M Patent Suit Cost Deduction
• Texas Says Planned Parenthood Can't Get Atty Immunity
• Class In Bayer 'One A Day' Gummies Lawsuit Gets Judge's OK
• 8th Circ. Won't Pause FTC's Insulin Pricing Case
• MiMedx Challenges FDA Classification Of Wound Care Powder
• 6th Circ. Judge Skeptical Of Mich. Newborn Screening Ruling
• Oracle Eyes Stake In TikTok's US Entity, And More Rumors
• Medical Malpractice Insurers Ink $1.3B Merger Deal
• Performing Stand-Up Comedy Makes Me A Better Lawyer
• Ohio Judge Blasts Fla. Atty In Opioid MDL For False Statements
• Sotera Beats Shareholder Suit Over Sterigenics Emissions
• Unpacking The Illicit E-Cigarette Crackdown By State AGs
• Lawmakers Shouldn't Overlook Rare Disease Therapies' Value
• Ohio Opioid Judge Says Texas Court Should Hear Appeal Bid
• Adapting To Private Practice: From SEC To BigLaw
• Pillsbury Adds Commercial Deal Pro From A&O Shearman
• Law360 Announces The Members Of Its 2025 Editorial Boards
• Advanced Instruments Buys Nova Biomedical In $2.2B Deal
• Purdue Pharma Files New $7.4B Ch. 11 Plan Settlement
• Emisphere, Novo Nordisk Sale Suit On Track For Settlement
• ITC To Review Whether Tourniquet Importers Are Ignoring Ban
• Full 9th Circ. Mulls Reviving Workers' LA Schools Vax Fight
• Drugmaker's $10.5M Deal In Investor FDA Approval Suit OK'd
• HHS Seeks Early Win Over Lilly, Novartis, BMS In Rebate Row
• Lab Co-Founder Takes Stand For Gov't In $40M Testing Case
• J&J Denies 'Evil Motive' In Face Of $30M Talc Damages
• Ga. Hospital Failed To Protect Data Of 120K, Patient Says
• Bausch Eye Vitamin Case Should Go To Jury, Judge Says
• China High Court Ruling Could Encourage Antitrust Litigation
• MilliporeSigma Says Rival Raided Workers Under Non-Solicits
• AI Healthcare Co. Accuses Test-Maker Of Infringing Patents
• States Oppose Term In Sandoz Price-Fixing Deal With Fla.
• Indirect Effexor Buyers Seek Approval Of $2.3M Antitrust Deal
• Greenberg Traurig Boosts Litigation Team With 4 Denver Attys
• Making The Case For Rest In The Legal Profession
• Novartis Nabs Partial Ban Against MSN's Heart Drug Generic
• Ex-Opioid Co. CEO Wants Out Of Law Firm's Billing Suit
• New Bills Target 'Patent Thickets' And 'Product Hopping'
• Doctor Pays $700K To Settle Feds' Medicare Fraud Suit
• Jazz Inks Insurer Class Deal As Xyrem Antitrust Trial Nears
• Court Won't Toss Biotech Co.'s Antitrust Counterclaim
• Full 7th Circ. Won't Revive Suit Over Late Medicaid Payments
• How Amended Rule 702 Affects Testimony In Patent Litigation
• What Trump's Order Means For The Legal Status Of IVF
• NC AG Fights TikTok's Early Exit From Addiction Suit
• Yale Says Researcher's Omissions Doom $28M Incubator Suit
• Mitigating Tariff Risks For Healthcare In US And Canada
• Austrian Biotech BIA Hits Ch. 15, Says Exec Stole $22M
• Seeger Weiss Atty Tapped To Lead Depo-Provera Plaintiffs
• 4 Firms Guide Up To $1.14B Sale Of PE-Backed Biotech
• 4 Ways Women Attorneys Can Build A Legal Legacy
• PTAB Explains Why It Invalidated Moderna's COVID Vax Patents
• Market Turbulence Threatens To Stall IPO Recovery
• Ex-NJ Health Official Settles Suit Over COVID Whistleblowing
• Fed. Circ. Affirms No Block On Amgen's Eye Med Biosimilar
• Antigua Clinic Accused Of Lying About 'Miracle' Cancer Cure
• Biotech Wins Dismissal Of Investor Fraud Claims
• 1st Circ. Asked To Look At Takeda Invoice Fraud Conviction
• Green Groups Sue Fed. Agencies Over Frozen Funding
• FTC Urges 8th Circ. Not To Pause Insulin Pricing Case
• Dr. Oz Pledges 'Upcoding' Crackdown If Confirmed At CMS
• A Judge's Pointers For Adding Spice To Dry Legal Writing
• Colo. Jury Rejects Claims Sterilization Co. Caused Cancer
• Taxation With Representation: Davis Polk, Paul Weiss
• Preparing For Disruptions To Life Sciences Supply Chains
• SEC's Expansion Of Confidential Filings Likely To Spur Deals
• Fed. Circ. Sides With Merck In Reissued Patent Debate
• Merck Asks Justices To Block Fosamax Failure-To-Warn Suits
• Calif. AG Appealing State Limits On Pay-For-Delay Ban
• Fed. Circ. Dings Antibody Patent App For Lacking Description
• PBMs Tell FTC 5-Month Delay Too Long For In-House Insulin Trial
• HHS Calls Back Terminated Attys Clearing Medicare Appeals
• 9th Circ. Ends Idaho Abortion Law Row After Mutual Dismissal
• Mastering The Fundamentals Of Life Sciences Due Diligence
• Beware Risks Of Arguing Multiple Constructions In IP Cases
• 6 Firms Steer $6.7B Mallinckrodt, Endo Pharma Merger
• Full 4th Circ. Urged To Rethink Drug Price-Fixing Class Action
• J&J Unit Drops Noncompete Suit Against Ex-Marketing Exec
• Days Into New Role, FDA's Top Lawyer Is Out
• Lacking Votes, White House Pulls Weldon Nomination At CDC
• Cancer Cause Or Red Herring? Jury Weighs Plant Bellwether
• Del. Justices Told Conflicts Tainted AstraZeneca Co.'s $3B Sale
• Labcorp Warns Fed. Circ. Of 'Balkanization' In Prenatal IP Row
• Law360 Cheat Sheet: Novartis' Fight Over Generic Entresto
• SEC Says Ex-Allarity Execs Concealed Doomed FDA Approval
• Caribou Biosciences Brass Face Investor's Clinical Trials Suit
• COVID Test Device Maker Settles Fed. Circ. Feuds With Rival
• Publix Policies Don't Cover Opioid Claims, Court Says
• NC Organ Procurer Sues CMS Over Hospital Waiver
• What's At Stake In High Court Transgender Care Suit
• Cannabis Tech Co. Seeks Over $1M Interest On $4.2M Verdict
• HHS To Eliminate 6 Regional Offices For Legal Staff
• Harvard Docs Say Gov't Censored Articles With Gender Terms
• Mallinckrodt Investors Ask NJ Court To Approve $46M Deal
• McCarter & English Wins $3.77M From Ex-Client In Billing Spat
• 6th Circ. Ruling Paves Path Out Of Loper Bright 'Twilight Zone'
• Medical Device Co. Seeks Fed. Circ. Redo Over Patent Trial
• Kenvue Unit Can't Nix BIPA Suit Over Neutrogena Skin360 App
• 'Paucity' Of Proof Thwarts NC State Law Claims In Gardasil MDL
• More ITC Patent Cases Expected After Fed. Circ. 'Sea Change'
• Pharmacies To Appeal In Bid To Keep Making Weight Loss Drug
• J&J Tells 3rd Circ. No Price Impact In Talc Concealment Suit
• Brazilian 'Drug King' Ran Black Market Pharmacy, Feds Say
• Zydus Cuts Deal With States, Tribes In Opioid Nuisance Suit
• Eli Lilly Suit Over Compounded Drugs Survives Dismissal
• A Reminder On Avoiding Improper Venues In Patent Cases
• Alaska's RICO Claims Advance Against PBM In Opioid Suit
• Post Hit With False Ad Suit Over Rachael Ray Brand Pet Food
• Endo Sells International Pharma Biz To Knight For Up To $99M
• Publix's Suit Over Ga. County's Private Attys 'Beyond Reason'
• Trump Admin Drops Suit Over COVID Nasal Spray Ads Claims
• Sullivan & Cromwell Hires Ex-FTC Deputy Director In Palo Alto
• Ex-J&J Atty Says She Was Fired For Making Ethics Complaint
• White House Names Ex-Goldman Sachs Atty To Lead USPTO
• Illinois Judge Floats Sanctions In Akorn Mootness Fee Fight
• Amgen, Fresenius Settle Osteoporosis Drug Patent Dispute
• Masimo Founder Urges Toss Of 'Empty Voting' Suit
• Calif. Pharma Exec Pleads Guilty To Insider Trading
• DOJ Wants In On Invisalign Monopoly Arguments At 9th Circ.
• NIH Cuts To Indirect Costs May Stifle IP Generation
• Recent Cases Clarify FCA Kickback Pleading Standards
• Antitrust Analysis In Iowa Pathologist Case Misses The Mark
• GAO Says NIH Treated Bidders Disparately On $20M IT Deal
• CBD Co. Launches More Patent Suits Over Topical Cream
• Fed. Circ. Won't Pause Teva Patent Delisting For Appeal
• Ex-Magellan CEO Pleads Guilty Over Faulty Lead Tests
• FDA Can Take Eli Lilly Weight Loss Drug Off Shortage List
• AGs Say Anti-Trans Admin Puts $367M Hospital Grants At Risk
• Hints Of A New High Court Majority Emerge In Trump Cases
• Ohio, PBMs Say High Court Ruling Didn't End Pricing Appeal
• New Bellwethers Score Cert. In Generic Drug Price-Fixing MDL
• Apple Prevails In Watch Tech Patent Fight At Fed. Circ.
• Ex-Novo Nordisk Worker Can't Reopen Harassment Suit
• Tariffs, Diversity And DOGE Dominate Trump 2.0 'Risk Factors'
• State FCAs Should Cover Local Fund Misuse, State Tax Fraud
• Husband Of Ex-Takeda VP Gets 2½ Years For Invoice Scam
• Taxation With Representation: Kirkland, Wachtell, Skadden
• Don't Give Teva 'Eighth Bite' At $235M Patent Trial, GSK Says
• Pfizer Failed To Warn Of Depo-Provera's Tumor Risk, Suit Says
• Wheeling & Appealing: The Latest Must-Know Appellate Action
• FTC Challenges PE Firm's Medical Device Coatings Deal
• Walgreens Boots Inks $24B Go-Private Deal With Sycamore
• No Cancer Therapy Patent For AbbVie, Says Federal Circuit
• Attys Seek $30M Fees In Walgreens Rx Overcharge Deal
• 7 Tips For Associates To Thrive In Hybrid Work Environments
• FDA Nominee Hedges On Job Cuts, Abortion Drug In Hearing
• Kirkland-Led Medical Device Firm Prices Upsized $202M IPO
• Trump Administration Ordered To Release Funds To States
• Playing Beach Volleyball Makes Me A Better Lawyer
• Celltrion Can't Undo Eye Med Biosimilar Injunction On Appeal
• Teva Wants Pause Of Patent Delisting For High Court Appeal
• Pfizer Beats Claims Of Copay Aid Scheme For Good
• Nationwide Block Of Trump Trans Healthcare Orders Extended
• Biotech Co. Maravai Hit With Investor's Internal Controls Suit
• Senators Press Trump's NIH Nominee On Grant Cuts, Vaccines
• Pfizer, BioNTech Get PTAB To Invalidate Moderna Vaccine IP
• Trump's NIH Cost-Cutting Measure Blocked By Judge
• 3 Firms Build Jazz Pharmaceuticals' $935M Chimerix Buy
• Skin Care Tech Co. Files Ch. 11 With $400M Prepackaged Plan
• Meijer Says 1st Circ. Must Resolve Takeda Arbitration Order
• Gov't Says 2 Lab Owners Billed $40M In COVID Test Scheme
• Apple Seeks Ban Against Masimo's Original Smartwatch
• Fed. Circ. Affirms PTAB Decision Backing Stem Cell Patent
• Moderna Faces MRNA Vax Patent Suits In Canada And Beyond
• Alcon, Lens.com Settle 7-Year Trademark Fight In NY
• PBMs Ask 8th Circ. To Pause FTC's Insulin Pricing Case
• After 'Historic Low' In 2023, Number Of ITC Cases Soar In 2024
• What To Expect From 'Make America Healthy Again' Actions
• In Rare Move, Texas Judge Shuns Out-Of-State BigLaw Attys
• Freezer Co. Drops Supplier Suit Over $15M Embryo Loss
• How Law Firms Can Counteract The Loneliness Epidemic
• Colo. Biotech, Founders Owe SEC $14.3M Over Fraud Claims
• What's At Stake In High Court's Class Member Standing Case
• IRS Asks To Toss Abbott Labs' FOIA Action For Tax Records
• Lead Testing Operations Chief To Admit Misbranding Charge
• Feds Seek 40 Mos. For Husband Of Ex-Takeda Exec
• Ultragenyx Loses Bid To Toss Suit Over Henrietta Lacks' Cells
• Full Fed. Circ. Won't Take On Teva's Orange Book Appeal
• Sandoz Settles Florida's Generic Drug Price-Fixing Claims
• Teva Should Face Key Copaxone Antitrust Claims, Court Told
• Sanofi Grilled By Judge Over $1.2M In Amgen Patent Saga
• Calif. Farm Sues Tenn. Sheriff Over $3.9M In Destroyed Hemp
• Boston Scientific Buying $600M Ultrasound System Developer
• 5 Mass. Rulings You May Have Missed In February
• How Citizen Petitions Have Affected Drug Competition
• Convicted Drexel Professor Gets 2 Years For Tax Evasion
• Vape Co.'s Challenge Of FDA Penalty Rejected
• 5 Keys To Building Stronger Attorney-Client Relationships
• Jones Day Hires Pair Of Weil IP Litigators In California
• 3rd Circ. Preview: Litigation Funder, J&J Seek Relief In March
• Life Science Consulting Firm Hits Ch. 11 With Sale Plans